ImageneBio Inc (IMA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.5x

Market Cap

$54.94M

MomentumView details →

1D Return

−0.92%

YTD Return

−29.28%

RSI (14)

30.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.5x

Market Cap

$54.94M

RSI (14)

30.2

MomentumView details →

1D Return

−0.92%

YTD Return

−29.28%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−36.94%

ROA (TTM)

−34.52%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−3.37%

FCF YoY

−97.84%

Revenue CAGR 3Y

−62.86%

EPS CAGR 3Y

+76.21%

EBITDA YoY

−28.10%

EarningsView details →

EPS (Actual)

−$0.63

EPS Surprise

35.50%

Beats (12Q)

9/12

Next Q EPS Est

−$0.79

Avg Surprise (4Q)

−10.26%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

21.47x

Quick Ratio

21.47x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−52.48M

Op. CF (TTM)

−57.73M

Next earningsNov 11, 2026 →

Latest newsMore news →

ImageneBio, Inc. reported its Q2 2026 financial results, with zero revenue, a net loss of $10.2 million, and a diluted loss per share of $0.63.31d ago

Similar companies

China Regenerative Medicine International Limited08158.HK Kezar Life Sciences, Inc.KZR Immutep LimitedIMMP Seres Therapeutics, Inc.MCRB Coeptis Therapeutics, Inc.COEP MiNK Therapeutics, Inc.INKT Find similar companies →

Latest newsMore news →

ImageneBio, Inc. reported its Q2 2026 financial results, with zero revenue, a net loss of $10.2 million, and a diluted loss per share of $0.63.31d ago